The investigators designed this study to evaluate the efficiency and the acute toxicities of recombinant human endostatin (endostar) combined with chemotherapy in the metastatic nasopharyngeal carcinoma (NPC).

PFS means assignament to the date of any local or distant progress of the disease useing Kaplan-Meier caculate the progress free survival rates

Secondary Outcome Measures:

overall survival(OS) [ Time Frame: baseline to date of death from any cause ] [ Designated as safety issue: No ]

the overall survival denote to assignment to date of death from any cause. Using Kaplan-Meier to caculate the 1-year ,2-year,3-year overall survival rate

Adverse events [ Time Frame: participants will be followed for the duration of hospital stay,an expected average of 100 days and every 3 months thereafter for 1 year ] [ Designated as safety issue: Yes ]

observe and record the toxicity profile(incluing but not limit to mocositis,liver and kidney function,et al.)according NCI-CTCAE(3rd edtion) during the chemotherapy,Targeted therapy and follow-up

Diagnosed metastatic NPC patient who have received radiotherapy or chemoradiotherapy with an at least 6 months interval

Have measurable lesions

No dysfunction of the major organs

Can understand this study and give a signed informed consent certificates

without a history of allergic reaction to the biological agents

Exclusion Criteria:

Pregnant or lactating women; Women of child-bearing age without contraception

with a Serious infection or dysfunction of the major organs

have taken other antitumor drugs during the period of 30 days ahead of this clinical trial

allergic to the Escherichia coli preparations

Cann't understand this study and give a signed informed consent certificates

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01612286